Mudit Chowdhary, MD @ParikhSimul Hands down my favorite trial in the colorectal space. The Germans have their finger squarely on the pulse! #radonc

If Bobby Wagner signs with the Rams, we will Paypal one lucky follower $25 - Follow and like this tweet to enter - Retweet for an additional entry Photo via Robert Robinson

🚨 New #RadOncCalc update available (for free) in the Android Market & App Store!🚨 📌 Now displays BT & Re-RT data. 📌 Now displays volume ranges in % & cc's. 📌 Many other updates! Can we do better? Please let us know via DM or by hitting the➕sign in the app. Enjoy! 1/3

All of this commentary about the omission of RT being valid with only 5 years of follow-up LUMINA when even EBCTCG data says the maximum benefit of AI in years 1-4 is highly problematic. Modern RT is nontoxic and can be delivered in 5 days for most omission candidates. #bcsm

Here's our series of children treated with craniospinal RT using ELECTRONS ⚛️for spinal fields since 1983. sciencedirect.com/science/articl… -84 pts, 48 followed for ≥ 5 yrs -MC histology: Medulloblastoma/PNET (59%) -Median age at RT 5 yrs -Median follow up 19 yrs

Excited to share the first prospective study of MR guided RT in #PancreaticCancer IJROBP - The Red Journal. Ablative RT with concurrent full dose chemo. All tumors abutted at least 1 OAR. 2-yr LC 85%. Median OS for ECOG 0 and CA 19-9<90 pts were 34 and 43 mos. sciencedirect.com/science/articl…

Congratulations Dr. Deek Matthew P Deek Rutgers Radiation Oncology Residency Program Rutgers Cancer Institute Rutgers RWJMedSchool for his study on oligometastatic disease in prostate cancer published Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Dr. Deek Matthew P Deek Rutgers Radiation Oncology Residency Program Rutgers Cancer Institute now presenting in Bio 2 - Genomics and Molecular Biomarkers. #ASTRO22 ASTRO

Very interesting work by Linda Cao (R5 Johns Hopkins University) at #astro22 using Elekta CORE OMD multicentre database: ✅ LC predictive of progression and OS ✅ GTV/ITV Dmin a/b 60 most predictive of LC ✅dose thresholds for 95% LC in radioresistant histologies #radonc

Pleased to share our latest work in IJROBP - The Red Journal examining costs of radiotherapy under the Oncology Care Model. This was a fantastic collaboration with Nikhil G. Thaker, MD and the team at Arizona Oncology. redjournal.org/article/S0360-…

Sharing our recent work on brain metastases from biliary tract cancers, led by outstanding Baylor medical student Grace Dodoo and senior authors Eugene J. Koay, MD, PhD and Ethan Ludmir MD

TACE vs. SBRT for HCC: randomized phase II TRENDY trial - stoped early due to poor a accrual - all endpoints significantly or numerically better after SBRT 👉 time to progression 19 vs 12 mo 👉 median OS 44 vs 37 mo 👉2a local control 100% vs 44% CONGRATS redjournal.org/article/S0360-…

🎙️ cN+ M0 #bladdercancer (BCa) had equivalent survival outcomes whether treated w/ 🔪 or radical RT‼️OncoAlert ASTRO ASCO 📌Multi🏬retro analysis 287👥survival outcomes 🥇🎯: TMT vs. radical cystectomy (RC) in cN+ M0 BCa 📊RESULTs 👉⬆️ OS for👥 receiving radical

🎙️ PBT hás similar OS, but ⬆️ PFS and LC compared to TACE for #HCC❗️❗️ 🚨OncoAlert 📌Ph3 RCT: TACE vs PBT for #HCC -PBT:70.2Gy/15fx, TACE until max response 🥇🎯:OS 📊RESULTs 👉2-y OS :68% PBT vs 65% TACE 👉PBT ⬆️ PFS & LC than TACE 👉Post-treatment hospitalization

☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer eClinicalMedicine – The Lancet Discovery Science ➡️45 patients ✅R0 resection: 80% vs. 20%, P < 0.001 ✅3-year PFS: 76% vs. 45% , P = 0.049 ✅3-year OS: 87.6% vs. 75% , P = 0.037 ✅No differences in severe AEs ❗️Study was